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Abstract
Introduction: Adolescents are at increased risk of HIV virological non-suppression compared to adults and younger children.
Common mental disorders such as anxiety and depression are a barrier to adherence and virological suppression. The aim of
this study was to identify factors associated with virological non-suppression among adolescents living with HIV (ALWH) in
Zimbabwe who had symptoms of common mental disorders.
Methods: We utilized baseline data from a cluster-randomized controlled trial of a problem-solving therapy intervention to
improve mental health and HIV viral suppression of ALWH. Sixty clinics within 10 districts were randomized 1:1 to either the
intervention or control arm, with the aim to recruit 14 adolescents aged 10 to 19 per clinic. Adolescents were eligible if they
scored ≥7 on the Shona Symptom Questionnaire measuring symptoms of common mental disorders. Multivariable mixed-
effects logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for factors associated
with non-suppression, defined as viral load ≥1000 copies/mL.
Results: Between 2 January and 21 March 2019 the trial enrolled 842 participants aged 10 to 19 years (55.5% female,
58.8% aged <16). Most participants (N = 613) were taking an NNRTI-based ART regimen (13 PI-based, 216 unknown) and
median duration on ART was six years (IQR three to nine years, 240 unknown). Of the 833 with viral load data 292 (35.1%)
were non-suppressed. Virological non-suppression was independently associated with male sex (adjusted OR (aOR) = 1.43,
95% CI 1.04 to 1.97), and with not knowing one’s own HIV status (aOR = 1.77, 95% CI 1.08 to 2.88), or knowing one’s status
but not disclosing it to anyone (aOR = 1.99, 95% CI 1.36 to 2.93), compared to adolescents who knew their status and had
disclosed it to someone.
Conclusions: ALWH with symptoms of common mental disorders have high prevalence of virological non-suppression in Zim-
babwe, especially if they do not know their status or have not disclosed it. In general adolescents should be informed of their
HIV status, with encouragement on the beneficial health and social effects of viral suppression, to incentivise adherence.
Efforts to strengthen the operationalization of disclosure guidelines for adolescents should now be prioritized.
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1 | INTRODUCTION
Adolescents (defined as aged 10 to 19 years), are the only
age group in which, globally, HIV mortality is not falling [1].
Adolescents on antiretroviral therapy (ART) appear to be at
higher risk of virological non-suppression than adults, although
evidence is limited. A systematic review in 2016 found only
20 papers reporting prevalence of virological suppression in
adolescents aged 10 to 19 [2], and only seven papers from
eastern and southern Africa where 70% of adolescents living
with HIV (ALWH) reside [3]. A review of clinic records of
5715 adolescents aged 10 to 19 in Kenya found 33% were
virologically non-suppressed (viral load ≥1000 copies/µl) [4]. A
baseline survey from a cluster-randomized trial in Zimbabwe
found that 46.8% of 496 adolescents on ART aged 13 to 19
were non-suppressed at baseline [5], compared to 14.7%
among adults in a national survey [6].
ALWH face numerous challenges to virological suppression.
Adolescents with perinatally acquired HIV may have been
exposed to monotherapy for prevention of mother to child
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transmission, followed by long-term ART. Young adolescents
are also vulnerable to over- or under-treating due to prescrip-
tion errors in weight-based regimens. For example, a study of
309 children aged 0 to 17 years in Zimbabwe on weight-
based ART regimens found 36% were prescribed an incorrect
dose [7]. Adolescents face additional challenges to ART adher-
ence [8]. In a period of rapid cognitive and emotional develop-
ment, emerging autonomy and limited resources [9],
adolescents rely on family and social support to adhere to
ART. They may be unaware or have limited understanding of
their HIV status, reducing their motivation or capacity to
adhere [10]. A study of 385 children aged six to fifteen in
Zimbabwe found that 47.5% (n = 183) were unaware of their
HIV status and the most common reasons caregivers gave for
secrecy were that the child was too young (62%), would not
understand the implications of an HIV diagnosis (56%), or
might disclose it to others (26%) [11]. Adolescents may also
conceal their treatment taking from others, which can practi-
cally impede their capacity to adhere [12]. ALWH have high
rates of depression, anxiety and other common mental disor-
ders (CMDs) [10], which inhibit adherence. A cross-sectional
study of 562 adolescents aged 12 to 18 in Malawi found
18.9% prevalence of depression using the Beck Depression
Inventory II [13]. There is evidence ALWH are at higher risk
of CMDs than their HIV-unaffected peers, for example from a
case-control study in Rwanda that found 21% prevalence of
suicidal behaviour among 218 ALWH aged 10 to 17 compared
to 13% among neighbours unaffected by HIV, using the Youth
Self-Report Internalizing Subscale [14]. Parent-reported symp-
toms of CMDs on the Pediatric Symptom Checklist were
associated with virological non-suppression in a cross-sectional
study of 692 children aged 8 to 16 in Botswana, although
causality could not be determined [15]. Better understanding
of risk factors for virological non-suppression is needed in
order to identify barriers and improve care outcomes. The aim
of this study was to measure the prevalence of and identify
risk factors for virological non-suppression among ALWH with
CMD symptoms in Zimbabwe.
2 | METHODS
The data for this paper are from the baseline survey of a
cluster-randomized controlled trial of problem-solving therapy
for adolescents which has been described in detail [16]. We
present the descriptive characteristics of trial participants and
factors associated with unsuppressed viral load, defined as
≥1000 copies/mL.
The trial was based in the World Health Organization
(WHO) “best practice” [17] Zvandiri programme of trained,
mentored young people known as community adolescent
treatment supporters (CATS). We undertook a cluster-
randomized trial of the CATS intervention with 60 clinics ran-
domized 1:1 within 10 districts to either the intervention or
control arm. Control arm participants received standard of
care from the CATS. In the intervention arm, CATS were
trained in an adaptation of Friendship Bench problem-solving
therapy. The eligibility criteria were as follows: ALWH aged
10- to 19-years old, on or initiating ART, who scored ≥7/14
on the Shona Symptom Questionnaire (SSQ-14) of CMD
symptoms [18]. Adolescents were excluded if they lived
outside the area, were unable to comprehend the nature of
the study (in either English, Shona or Ndebele), were in psy-
chiatric care, or had end-stage AIDS, psychosis, intoxication or
dementia. Potential participants (adolescents either already
registered with Zvandiri or who were patients at the clinic)
were pre-screened for eligibility and then invited to a trial ori-
entation meeting. Those who were interested were screened
for CMD symptoms by a research assistant. Enrolment ended
when 14 participants had been enrolled. Participants aged 18
to 19 gave written informed consent. Those aged 10 to 17
gave written assent, and written informed consent was given
by their caregiver.
A questionnaire was administered which included demo-
graphic, family and clinical characteristics, SSQ-14 to measure
symptoms of CMDs, the Patient Health Questionnaire (PHQ-
9) to measure symptoms of depression, and the WHO Disabil-
ity Assessment Schedule (WHODAS 2.0) to measure difficul-
ties caused by health conditions. The SSQ-14 scores 1 point
for each of 14 symptoms experienced within the previous two
weeks [18]. Validated against the MINI-KID in Zimbabwean
ALHIV, the SSQ-14 has a cutpoint of ≥8 (unpublished data).
The PHQ-9 consists of 9-items measuring depression symp-
toms, each scored 0 to 3 on a Likert scale, with the total
score (range 0 to 27) categorized into five groups [19]. It has
been validated among adolescents in Chile [20]. The WHO-
DAS 2.0 consists of 36 questions covering six domains (cogni-
tion, mobility, self-care, getting along, life activities, social
participation) [21]. It has been validated among adolescents in
China [22]. Following that study, the question on sexual activi-
ties was dropped as it was not appropriate for the whole age
group.
Adolescents with signs of psychological distress (visual/audi-
tory hallucinations or suicidal ideation on the SSQ-14, or ≥21
on the PHQ-9) were referred to the clinic for further assess-
ment and management, including follow-up by a trained men-
tal health nurse where available.
It was intended that data collection would be electronic,
using an Open Data Kit (ODK) programme loaded onto
tablets [16]. During recruitment a fault occurred which pre-
vented the data management team from accessing uploaded
data. From then on the study used the back-up option of
paper-based data collection. Initially the processes of recruit-
ment, consent procedures and the enrolment questionnaire
were carried out by research assistants. After the switch to
paper-based data collection they were conducted by the
CATS. Separate questionnaires were printed for participants
who knew their own status and those who did not, with the
“knows HIV status” version including a small number of extra
questions such as ART regimen and date of HIV diagnosis. The
“does not know status” version instead had questions such as
whether the participant was taking any medication. The inter-
viewer decided which questionnaire to use, based on whether
the participant knew their own status, as logged in clinic
records and reported by the caregiver. Double entry and vali-
dation of paper records was completed by a private company,
Datalyst. The questionnaires are available for download
(doi.org/10.17037/data.00002142).
A dried blood spot (DBS) fingerprick blood sample was col-
lected from all participants and analysed at the National
Microbiology Reference Laboratory to determine viral load.
The minimum detection level was 840 copies/mL. Viral load
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results were returned to the clinics to aid in clinical manage-
ment. Guidelines in Zimbabwe call for routine viral load test-
ing to be carried out at 6 and 12 months after ART initiation,
and then annually [23]. In case of virological failure (viral load
≥1000 copies), patients are given enhanced adherence coun-
selling, a repeat viral load test after three months, and a
switch to second line therapy if viral load remains high. Transi-
tion to third line therapy requires genotypic resistance testing,
which is only available at one clinic.
Data were analysed using Stata v15. The WHODAS domain
scores were recoded into “no problem” (score of 0) and “any
problem” (score ≥1). A report of visual/auditory hallucinations
or suicidal ideation on the SSQ-14 was designated a “red flag.”
The PHQ-9 “moderately severe” (score 15 to 19) and “severe”
(20 to 27) categories were combined due to small numbers.
Univariable mixed-effects logistic regression was used to iden-
tify variables associated with virological non-suppression, with
a random effect to allow for clinic-level clustering. Factors
associated with the outcome at significance level >10% were
carried forward into a multivariable model, with age and sex
retained a priori. Variables that were no longer associated with
the outcome in multivariate analysis (p > 0.1) were removed.
Knowledge of HIV status was defined as a participant who
either (i) was pre-determined by CATS to know their HIV sta-
tus, based on clinic notes or (ii) when asked why they were
taking medication, responded “for HIV.” Disclosure of status
was defined as a participant who answered yes to the ques-
tion “have you disclosed your HIV status to anyone” on the
“knows HIV status” version of the questionnaire. Knowledge
of status and disclosure to others were combined into a single
categorical variable for the multivariable analysis to avoid
collinearity. EQ5D scores were converted into index values
[24] using quality of life state weightings developed in Zim-
babwe in 2003 [25]. The association between age group and
HIV status knowledge was estimated using odds ratio.
The trial was registered with the Pan African Clinical Trials
Registry (PACTR201810756862405), and approved by the
ethics committees of the Medical Research Council of Zim-
babwe and the London School of Hygiene & Tropical Medi-
cine.
3 | RESULTS
Data collection took place between 2 January and 21 March
2019. The trial enrolled 842 participants (55.5% female), 84
per district in nine districts and 86 in the tenth (Figure 1).
The first 232 (27.6%) questionnaires were completed elec-
tronically by a research assistant and the remaining 610
(72.4%) on paper by the CATS. The mean number of partici-
pants per clinic was 14.0 (standard deviation 2.7), range 6 to
22. Nine participants (1.1%) had no viral load test result. Of
these, one participant died and two withdrew between enrol-
ment and collection of a DBS sample, and for the remaining 6,
samples were collected but not analysed.
Half (49.8%) of participants were single or double orphans
(Table 1), and 474 (56.6%) participants’ primary caregiver was
not a parent. Among adolescents aged ≥16 years, 90.1% had
finished primary school and 3.9% were employed. Prevalence
of self-reported alcohol use and smoking increased with age,
and was 5.1% and 4.4%, respectively, in 16- to 19-year olds.
Overall 35.2% of participants (n = 296) had symptoms of
moderate, moderately severe or severe depression according
to the PHQ-9. The most common problems according to the
WHODAS were cognitive (91.9%), followed by social participa-
tion (88.3%), life activities (76.8%), mobility (72.6%) and self-
care (61.7%).
Of 209 participants who completed the “does not know HIV
status” questionnaire, 41 (19.6%) said they were taking medi-
cation for HIV and 10 (4.8%) said they were taking ART. A
further 121 (57.9%) said they were taking medication but said
it was for another reason, they did not know why, or did not
give a reason. In Tables 1 and 2, the definition “knows HIV
status” consisted of the 633 participants who completed a
“knows status questionnaire” plus the 51 participants who
completed a “does not know status” questionnaire but said
unprompted that they were taking HIV medication or ART.
ART regimen was known for 626 participants of whom 613
(97.9%) were taking an NNRTI-based regimen. For 602 partic-
ipants whose year of ART initiation was recorded, median
length on ART was six years (IQR 3 to 9 years, range 0 to
18).
The proportion of adolescents who knew they were HIV
positive increased with age from 73.5% in 10- to 15-year olds
(the reference group) to 92.2% in 16- to 19-year olds
(OR = 4.83, 95% CI 2.98 to 7.82; p < 0.001). Most (59.2%)
adolescents who knew their own status had not told anyone
else, although the proportion who had disclosed was higher in
the 16 to 19 group (OR = 1.47, 95% CI 1.01 to 2.14;
p = 0.045).
Of the 257 adolescents who had disclosed their status, 251
reported to whom they had disclosed. The majority (197,
78.5%) had disclosed to a relative, 23 (9.2%) to a friend, 12
(4.8%) to a boyfriend/girlfriend and 21 (7.0%) to someone
else. Only 41 participants reported a reason for disclosing
their status, with the most common reasons being to receive
care and support (36.6%) or adherence support specifically
(29.3%).
Among the 833 participants with a viral load test result,
541 (64.9%) had a viral load <1000 copies/mL, 173 (20.8%)
1000 to 9999 copies/mL, 100 (12.0%) 10,000 to
99,999 copies/mL and 19 (2.3%) ≥100,000 copies/mL, with a
maximum of 788,592. The prevalence of virological non-
suppression was 35.1% (n = 292), ranging by district from
20.2% to 55.4%.
Males had higher odds of virological non-suppression than
females, (40.1% vs. 31.0%, OR = 1.43, 95% CI 1.04, 1.97;
p = 0.03) (Table 2). Figure 2 presents the prevalence of viro-
logical non-suppression by sex and district. There was no evi-
dence that virological non-suppression was associated with
age, education, primary carer or orphanhood, knowledge of
HIV status as a binary variable, ART regimen or duration on
ART (Table 2). Among participants who knew their HIV status,
non-disclosure was associated with non-suppression (39.0%
vs. 25.6%, OR = 1.99, 95% CI 1.36, 2.93; p < 0.001). In uni-
variable analysis, there was no evidence of an association
between depression symptoms score and virological non-
suppression (Table 2). Participants who reported difficulties
with life activities, social participation or cognition were less
likely to have virological non-suppression.
In the final multivariable model (Table 2), virological non-
suppression was independently associated with being male
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(adjusted OR = 1.43, 95% CI 1.04, 1.97; p = 0.03), not know-
ing one’s own HIV status (aOR = 1.77, 95% CI 1.08, 2.88;
p = 0.02) and not disclosing HIV status to someone else
(aOR = 1.99, 95% CI 1.36, 2.93; p < 0.001), compared to
those who knew their status and had disclosed it.
4 | DISCUSSION
Among these ALWH in Zimbabwe virological non-suppression
was very high (35.1%), demonstrating the challenges adoles-
cents face in attaining viral suppression. This is comparable
with the prevalence of virological non-suppression among
ALWH found in Kenya (33% of 5715) [4], and a previous
study in Zimbabwe found even higher prevalence (46.8% of
496) [5]. Three key factors were associated with virological
non-suppression: male sex, not knowing one’s own HIV status
and not disclosing HIV status.
Achieving viral suppression requires two essential elements:
access to effective treatment and optimal adherence beha-
viour. Access to effective treatment requires patients to be
able to get to the clinic, collect drug refills and be prescribed
an ARV regimen to which they are not resistant. Zimbabwe
has a “Treat All” approach whereby anyone with HIV is eligible
for ART initiation regardless of clinical stage or CD4 count,
and the preferred first line regimen at the time of data collec-
tion was TDF+3TC+EFV [23]. Resistance testing is sporadic
and is not yet a component of standard of care in Zimbabwe.
A WHO report in 2019 found pre-treatment drug resistance
to NNRTIs (efavirenz and nevirapine) in Zimbabwe of 11%
among 353 adult first-line ART initiators and over 60% among
227 newly diagnosed infants [26]. In 2016 in Harare, a volun-
tary organization-funded clinic provided enhanced adherence
counselling to 726 young people aged 16 to 24 on first-line
ART. After the counselling, 74 (10.2%) had confirmed virologi-
cal failure and 72/74 (97%) had drug resistance mutations
[27]. Out of 102 children and adolescents in Harare with
virological failure in 2012, 67.6% had ≥1 clinically significant
mutation [28]. There is increased emphasis on treatment
switching in international guidelines [29], informed by a grow-
ing recognition of high resistance rates among ALWH [30]. In
this study the highest prevalence of non-suppression, by far,
was in District 1, a border town with high HIV prevalence. It
is likely that participants travelled across the border for work
which may have hindered their access to ART. Reflecting the
mobility of youth populations, it is vital that clinics are flexible
in terms of supporting three-month drug refills and weekend
or after-hours clinic visits [31,32].
The second critical component in viral suppression is sus-
tained adherence. It is likely that the effects of sex, HIV status
knowledge and status disclosure on virological non-
suppression are caused by differential adherence behaviour. In
our study, males were at increased risk of non-suppression.
The finding is consistent with the literature from adults living
with HIV [33,34], and is increasingly noted within adolescents
too, in recent studies from Ethiopia [35], Malawi [36] and
Kenya [4]. However, a systematic review of adolescent ART
adherence in low and middle-income countries (8/15 studies
from sub-Saharan Africa) found no consistent association with
sex [8]. Healthcare is often perceived as “female” [37] and
underutilized by men [38]. Among adolescents too, boys are
less likely than girls to seek healthcare, possibly because boys
are socialized to more highly value being perceived as self-
reliant [39]. In KwaZulu Natal, South Africa, only 20% of 15-
to 19-year olds who visited clinics were male [40]. Boys and
men also have lower engagement in psychosocial support ser-
vices, indicating a need for tailored approaches to suit them
[38].
Participants who knew they were HIV positive had better
odds of virological suppression, in line with evidence that ado-
lescents who know their status have improved ART adherence
[41-43]. However, a systematic review of the effect of disclo-
sure on children’s adherence (aged 0 to 19) in resource-
limited settings found conflicting results [44]. One reason for
Figure 1. Map of trial sites.
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Table 1. Descriptive characteristics of trial participants by age group
10 to 15 years, n (%) 16 to 19 years, n (%) Total, n (%)
N 495 (58.8%) 347 (41.1%) 842 (100%)
Viral load (n = 833)
<1000 314 (64.1) 227 (66.2) 541 (65.0)
1000 to 9999 114 (23.3) 59 (17.2) 173 (20.8)
10,000 to 99,999 50 (10.2) 50 (14.6) 100 (12.0)
≥100,000 12 (2.5) 7 (2.0) 19 (2.3)
Sex
Female 270 (54.6) 197 (56.8) 467 (55.5)
Caregiver (N = 837)
Mother 144 (29.3) 85 (24.6) 229 (27.4)
Father 34 (6.9) 17 (4.9) 51 (6.1)
Both parents 49 (10.0) 34 (9.8) 83 (9.9)
Grandparent 179 (36.5) 109 (31.5) 288 (34.4)
Aunt 43 (8.8) 45 (13.0) 88 (10.5)
Other 42 (8.6) 56 (16.2) 98 (11.7)
How often changed household (N = 839)
Never 283 (57.3) 159 (46.1) 442 (52.7)
Once 119 (24.1) 98 (28.4) 217 (25.9)
Twice 61 (12.4) 56 (16.2) 117 (14.0)
3 times 18 (3.6) 14 (4.1) 32 (3.8)
4 times 5 (1.0) 8 (2.3) 13 (1.6)
5 or more times 8 (1.6) 10 (3.9) 18 (2.2)
Education level (N = 835)
Below grade 7 (primary) 267 (54.4) 34 (9.9) 301 (36.1)
Grade 7 (end of primary) 166 (33.8) 120 (34.9) 286 (34.3)
O level (secondary) 58 (11.8) 182 (52.9) 240 (28.7)
A level (upper secondary)/tertiary 0 8 (2.3) 8 (1.0)
Orphan (N = 840)
Both parents alive 256 (51.9) 166 (47.8) 422 (50.2)
One parent died 146 (29.6) 99 (28.5) 245 (29.2)
Both parents died 91 (18.5) 82 (23.6) 173 (20.6)
Knows their own HIV status
Yes 364 (73.5) 320 (92.2) 684 (81.2)
Disclosed HIV status to anyone (N = 630/684)
Yes 124 (38.2) 133 (43.6) 257 (40.8)
Drink alcohol (N = 814)
Yes 7 (1.5) 17 (5.1) 24 (3.0)
Smoke (N = 828)
Yes 5 (1.0) 15 (4.4) 20 (2.4)
Employed (N = 813)
Yes 4 (0.8) 13 (3.9) 17 (2.1)
HIV transmission (N = 653)
Vertical 190 (48.4) 163 (62.7) 353 (54.1)
Sexual/other 3 (0.8) 15 (5.8) 18 (2.8)
Don’t know 69 (17.6) 55 (21.2) 124 (19.0)
Not disclosed to 131 (33.3) 27 (10.4) 158 (24.2)
SSQ-14 score
Median (IQR) 8 (7 to 9) 8 (7 to 9) 8 (7 to 9)
SSQ-14 red flag
Yes 142 (28.7) 116 (33.4) 258 (30.6)
EQ5D index
Median (IQR) 0.83 (0.74 to 1) 0.83 (0.74 to 1) 0.83 (0.74 to 1)
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the inconsistency could be that “knowing one’s own HIV sta-
tus” can encompass a broad spectrum of stages of under-
standing what it means to be HIV positive [45], whereas most
studies (including this one) reduce it to a binary variable. Ado-
lescents who know they are living with HIV frequently have
little idea what that means for them, apart from a moral
imperative to take daily medication for life [46]. There is often
little discussion of what it will mean to grow up and live with
HIV, and after the revelation is made children are advised not
to think about their diagnosis [11,47]. In contrast, WHO guid-
ance recommends that caregivers should incrementally extend
children’s knowledge of HIV over time, in pace with their cog-
nitive and emotional development [48]. Further, enhanced
adherence counselling should be provided for all adolescents
with high viral load, to identify and address adherence barriers
and to prevent unnecessary regimen switching.
Caregivers of children with perinatally acquired HIV can be
reticent to tell the child their HIV status. Their concerns relate
to the impact they anticipate the knowledge would have on
their child, and also to the complex, relational entanglement
involved in the admission [49,50]. Caregivers and healthcare
staff can also underestimate adolescents’ understanding of liv-
ing with HIV [51]. In this study, participants’ responses to
questions about what medication they took and its purpose
revealed that at least 51 adolescents knew they were HIV
positive even though clinic records and caregivers said that
they did not know. Similar results have been found in South
Africa [52] and Uganda [53]. A qualitative study in Uganda
indicated that adolescents found their caregivers’ silence frus-
trating [49].
Viral suppression, achieved through optimal adherence, can
support thriving health and can be socially/relationally
enabling, by reducing physical signs of HIV and removing fears
of onward transmission [5,54]. Open discussion of the implica-
tions of an HIV status may help adolescents to “make sense”
of their lived reality [55], enable them to develop a realistic,
positive outlook for the future, and thereby have improved
mental health and wellbeing [53]. National guidelines state
Table 1. (Continued)
10 to 15 years, n (%) 16 to 19 years, n (%) Total, n (%)
Depression symptoms (PHQ-9)
Minimal (0 to 4) 104 (21.1) 59 (17.0) 163 (19.4)
Mild (5 to 9) 216 (43.7) 166 (47.8) 382 (45.4)
Moderate (10 to 14) 130 (26.3) 92 (26.5) 222 (26.4)
Moderately severe/severe (15 to 27) 44 (8.9) 30 (8.7) 74 (8.8)
WHODAS
Cognition
Any difficulty 455 (92.1) 318 (91.6) 773 (91.9)
Mobility
Any difficulty 363 (73.5) 247 (71.4) 610 (72.6)
Self-care
Any difficulty 326 (66.0) 192 (55.5) 518 (61.7)
Life activities
Any difficulty 390 (79.0) 256 (73.8) 646 (76.8)
Participation
Any difficulty 437 (88.5) 305 (88.2) 742 (88.3)
ART regimen and anchor drug
First line (NNRTI) 322 (97.3) 291 (98.6) 613 (97.9)
TDF 259 (77.1) 277 (92.3) 536 (84.3)
AZT 56 (6.7) 13 (4.3) 69 (10.8)
ABC 7 (2.1) 1 (3.3) 8 (1.3)
Second line (PI) 9 (2.7) 4 (1.4) 13 (2.1)
LPV/r 3 (0.9) 2 (0.7) 5 (0.8)
ATV 5 (1.5) 2 (0.7) 7 (1.1)
Unknown 1 (0.3) 0 1 (0.2)
Unknown 164 52 216
Duration on ART (years)
0 4 (1.3) 9 (3.1) 13 (2.2)
1 to 2 52 (16.9) 51 (17.3) 103 (17.1)
3 to 5 91 (29.6) 69 (23.4) 160 (26.6)
6 to 18 160 (52.1) 166 (56.3) 326 (54.2)
Unknown 188 52 240
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Table 2. Association of factors with virological non-suppression
N








Male 369 148 (40.1) 1.48 (1.10, 2.00) 0.01 1.43 (1.04, 1.97) 0.03
Female 464 144 (31.0) 1
Age (years)
10 to 12 230 78 (33.9) 1 0.50 1 0.40
13 to 15 260 98 (37.7) 1.18 (0.80, 1.74) 1.27 (0.83, 1.93)
16 to 17 176 55 (31.2) 0.87 (0.56, 1.35) 0.93 (0.58, 1.51)
18 to 19 167 61 (36.5) 1.13 (0.73, 1.75) 1.37 (0.84, 2.24)
Primary caregiver (N = 828)
Mother 225 81 (36.0) 1.27 (0.72, 2.25) 0.60
Father 51 21 (41.2) 1.47 (0.68, 3.18)
Both parents 82 24 (29.3) 1
Grandparent 287 99 (34.5) 1.24 (0.71, 2.17)
Aunt 86 36 (41.9) 1.59 (0.82, 3.10)
Other 97 29 (29.9) 0.95 (0.48, 1.85)
Religion (N = 822)
Catholic 91 36 (39.6) 1.57 (0.89, 2.77) 0.46
Adventist 83 30 (36.1) 1.30 (0.73, 2.34)
Methodist 62 22 (35.4) 1.30 (0.69, 2.48)
Pentecostal 267 89 (33.3) 1.08 (0.69, 1.69)
Apostolic 77 26 (33.8) 1.15 (0.61, 2.17)
ZCC 68 31 (45.6) 1.95 (1.05, 3.62)
None 24 9 (37.5) 1.20 (0.44, 3.26)
Other 150 46 (30.7) 1
Ever changed household (N = 830)
No 437 146 (33.4) 1
Yes 393 144 (36.9) 1.19 (0.88, 1.61) 0.26
Education
Below grade 7 297 110 (37.0) 1 0.33
Grade 7 284 103 (36.3) 0.94 (0.66, 1.34)
Secondary/Tertiary 245 76 (31.0) 0.75 (0.51, 1.11)
Orphan
No 417 141 (33.8) 1 0.58
One parent died 242 84 (34.7) 1.01 (0.71, 1.44)
Both parents died 172 66 (38.4) 1.22 (0.83, 1.79)
Knowledge/disclosure of HIV status
Knows status, disclosed 254 65 (25.6) 1 1
Knows status, has not disclosed to others 367 143 (39.0) 1.91 (1.31, 2.79) 0.001 1.99 (1.36, 2.93) <0.001
Does not know status 158 60 (38.0) 1.66 (1.05, 2.64) 0.031 1.77 (1.08, 2.88) 0.02
Drink alcohol (N = 806)
No 782 279 (35.7)
Yes 24 7 (29.2) 0.77 (0.30, 1.95) 0.58
HIV transmission
Vertical 348 111 (31.9) 1 0.20
Sexual 17 3 (17.7) 0.45 (0.12, 1.65)
Don’t know 123 50 (40.7) 1.43 (0.91, 2.26)
Other/unaware 335 124 (37.0) 1.21 (0.86, 1.71)
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that caregivers who find it difficult to disclose to the child
should be supported by healthcare workers [23], and this
aligns with evidence from systematic reviews [56,57].
In this study, adolescents who knew their own HIV status
but had not told anyone else were at almost twice the odds
of virological non-suppression after adjusting for covariates.
Similarly, in South Africa, non-disclosure was associated with
lower ART adherence [52]. Adolescents’ experiences of HIV
are typically characterized by isolation, stigma and shame,
which impede their adherence [12,58]. They are concerned to
protect social relationships by concealing their HIV status and
use of ART [59]. Many caregivers, and sometimes healthcare
workers, actively discourage ALWH from disclosing their sta-
tus, thereby cutting them off from potential sources of sup-
port [45]. Without access to formal HIV psychosocial support
[60], this further exacerbates the cycle of loneliness and sub-
optimal adherence. In this study, the most common reason
why adolescents disclosed their status was so they could










Depression symptoms (PHQ-9 category)
Minimal (0 to 4) 161 56 (34.8) 1 0.48
Mild (5 to 9) 378 126 (33.3) 0.90 (0.60, 1.36)
Moderate (10 to 14) 219 79 (36.1) 1.07 (0.67, 1.70)
Moderately severe/severe (15 to 27) 74 30 (40.5) 1.38 (0.74, 2.54)
SSQ-14
Red flag 256 96 (37.5) 1.14 (0.82, 1.59) 0.42
No red flag 577 196 (34.0) 1
EQ5D
No difficulty 280 93 (33.2) 1 0.15
Any difficulty (any score > 1) 435 148 (34.0) 1.00 (0.71, 1.40)
Severe difficulty (total score > 8) 116 50 (43.1) 1.53 (0.95, 2.48)
WHODAS cognition
Any difficulty 764 262 (34.3) 0.58 (0.33, 1.02) 0.06
No difficulty 68 29 (42.7) 1
WHODAS mobility
Any difficulty 603 204 (33.8) 0.83 (0.59, 1.17) 0.30
No difficulty 228 85 (38.2) 1
WHODAS self-care
Any difficulty 510 179 (35.1) 1.04 (0.76, 1.43) 0.81
No difficulty 3121 112 (34.9) 1
WHODAS life activities
Any difficulty 638 209 (32.8) 0.65 (0.45, 0.92) 0.02
No difficulty 194 82 (42.3) 1
WHODAS participation
Any difficulty 733 247 (33.7) 0.59 (0.37, 0.94) 0.03
No difficulty 98 44 (44.9) 1
ART regimen
TDF (first line) 536 173 (32.5) 0.73 (0.51, 1.04) 0.61
AZT (first line) 69 25 (37.3) 0.89 (0.49, 1.63)
ABC (first line) 8 3 (42.9) 1.16 (0.24, 5.58)
LPV/r (second line) 5 1 (25.0) 0.48 (0.05, 4.97)
ATV (second line) 7 2 (28.6) 0.64 (0.12, 3.61)
Unknown (second line) 1 1 (100.0) –
Unknown 216 87 (40.5) 1
Duration on ART (years) (N = 602)
0 13 3 (23.1) 0.45 (0.12, 1.75) 0.18
1 to 2 102 31 (30.4) 0.75 (0.45, 1.25)
3 to 5 159 45 (28.3) 0.65 (0.42, 1.01)
6 to 18 319 120 (37.6) 1
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Study participants who had disclosed their status to another
person reported more cognitive, life participation and self-care
problems on the WHODAS, indicating that disclosure can
have drawbacks as well as benefits. This is reflected in the lit-
erature, where adolescents often feel ambivalent about disclo-
sure, knowing it is inevitable at some point, but unsure how
to recognize the right time or person [61]. They need support
to make decisions about whom to tell and advice about how
to tell [62]. Disclosure of HIV status may pose substantial
risks for adolescents and damage social relationships [45],
with subsequent negative effects on adherence and mental
health [63]. In particular, the guidance to always disclose to
partners can be very challenging and may be a barrier to
remaining in care. Discussions of adherence could instead be
focused around U = U and the protective effects of viral sup-
pression [5].
The strengths of the study are that it consists of a large,
representative sample of adolescents in HIV care from all
over the country, including both urban and rural areas. CATS
established a rapport with participants which helped them col-
lect reliable self-reported data. The tools have been validated
in Zimbabwe, albeit in adult populations. The PHQ-9 and
WHODAS 2.0 have been validated among adolescents [20,22].
A limitation of the study is that it was a trial population. How-
ever, the response rate among those who were eligible for
enrolment was very high (97.6%), limiting selection bias.
Unsuppressed viral load was not confirmed with a second test
as recommended by the WHO. The study was cross-sectional
and temporal relationships cannot be established. The date of
ART initiation was not recorded and some participants may
have initiated ART within three months of enrolment, not
allowing sufficient time for viral suppression. The unplanned
switch from electronic to paper-based data collection caused
limitations. Data collection was done by the CATS rather than
by independent research assistants, and this could have led to
social desirability bias. Copies of paper questionnaires were of
poor quality and inconsistent formatting, causing problems
such as loss of item numbers, which made administration diffi-
cult. Some clinics ran short of questionnaires and may have
used a “disclosed” questionnaire when a “non-disclosed” one
was called for, adding to the confusion around knowledge of
status. The questionnaire was also long and burdensome for
children, especially the 30-item WHODAS which came last. As
a result, WHODAS information was unreliable. At follow-up
data collection these problems were resolved with the use of
robust electronic data collection systems.
5 | CONCLUSIONS
ALWH with symptoms of CMDs have poor virological sup-
pression in Zimbabwe. This could be improved by telling ado-
lescents their HIV status to incentivize adherence behaviour,
emphasizing the health effects of viral suppression and related
positive social/relational impacts of adherence. Global and
national guidelines recommend disclosure of HIV status to
ALWH. Strengthened operationalization of these guidelines is
needed to support adolescents’ mental health and incentivize
adherence behaviour. Adolescents should also be counselled
on the potential benefits and consequences of disclosing to
Figure 2. Prevalence of virological non-suppression by gender and district.
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others. Caregivers may benefit from advice on how to disclose
to adolescents that they are HIV positive and how to make
disclosure an ongoing, revisited conversation.
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